I-Semaglutide
Ekhulwini elidlule, imakethe yezidakamizwa ze-hypoglycemic iye yaba nezinguquko.Njengomkhiqizo othuthukiswe ngekhulu leminyaka elisha, ama-analogue e-GLP-1 asephenduke izinkanyezi ezikhazimulayo kakhulu emkhakheni we-hypoglycemic ngezinzuzo zomphumela omuhle kakhulu we-hypoglycemic kanye nomphumela omuhle wokuncipha kwesisindo.Phakathi kwazo, ukuncipha kwesisindo sekube enye imakethe enkulu engase ibe khona yezicelo zezidakamizwa ze-GLP-1.Njengamanje, iphethini yokuncintisana yabadlali abakhulu abaqondise ama-agonists e-GLP-1 receptor ekhaya naphesheya kancane kancane "iyashisa".Sizolinda sibone ukuthi ngubani ozohola futhi abambe imakethe.
Umjovo we-Semaglutide, uhlobo olusha lwe-agonist ye-receptor ye-glucose-1 (GLP-1) esebenza isikhathi eside, enokukhiqizwa kwe-insulin kanye nomsebenzi wokuvimbela ukugcinwa kwe-pancreatic hyperglycemia, izidakamizwa ezifanayo nazo zinenzuzo ku-Lutan peptide, i-ductal. peptide, njll.
NgoDisemba 2017, i-US Food and Drug Administration (FDA) yagunyaza ukufakwa kuhlu komjovo we-Smeglugan peptide ekulawuleni ukudla okusizayo nokuzivocavoca ukuthuthukisa ukulawulwa kweglucose yegazi ezigulini ezinesifo sikashukela sohlobo 2.Ngaphezu kwalokho, i-Novo kanye ne-Nord baphinde bathuthukisa uhlobo lwemithamo yomlomo i-Rybelsus ye-Smeglugin, futhi yagunyazwa okokuqala yi-FDA ngoSepthemba 2019. Lona futhi umuthi wokuqala ovunyelwe womlomo we-GLP-1 emhlabeni.isifo sikashukela.Empeleni, i-Smeglugin iyisidakamizwa se-hypoglycemic, kodwa ngenxa yokuthi izidakamizwa ezifana ne-Smeglugin peptide zinganciphisa isisu esingenalutho futhi zicindezele isifiso sokudla, zizonciphisa isisindo.
Ngenxa yalokhu, ngoJuni 2021, i-FDA yagunyaza ngokusemthethweni ukuphathwa kwesisindo sesikhathi eside sokukhuluphala noma abantu abadala abakhuluphele ngokweqile.Abantu abasebenzayo yilaba: iziguli ezilula ezine-BMI ≥30 kg/m2;kanye ne-BMI> 27 kg/m2 futhi ihlanganise okungenani inkinga eyodwa yokukhuluphala, njengomfutho wegazi ophezulu, uhlobo lwesifo sikashukela sohlobo 2, noma ama-lipids egazi angavamile.Kwakuyilokhu kugunyazwa ukuthi isithunzi sangcwatshwa i-Smeglugin emgwaqeni "womuthi wokunciphisa isisindo".
Ngo-Ephreli 2021, i-Smegugan yagunyazwa e-China ukulawula ushukela wegazi ezigulini ezinesifo sikashukela sohlobo 2 (T2DM).Nakuba inkomba yokulahlekelwa isisindo ingavunyelwe e-China, isidingo sokulahlekelwa kwesisindo sasekhaya asikwazi ukubanjelwa e-China.Ngaphezu kwalokho, ingqikithi eyinhloko "yobuncane ngomzimba omncane", engxenyeni yesibili ka-2022, i-peptide ye-Smeglugin "ayizange ivume" emkhakheni wokunciphisa umzimba., Once on multiple e-commerce platforms, it has set off the boom in buying, and once become high-priced "out of stock king", okwaholela ngokuqondile ezinkingeni zokukhiqizwa nokuhlinzekwa kwabakhiqizi.I-Nuo and Nord's July ngonyaka odlule yathi Ukuqaliswa kabusha kokuhlinzekwa kwezidakamizwa kuzomisa ukuhlinzekwa kwezimakethe ezingekho ezibhedlela.
Ukuduma kwe-peptide ye-Smegugu nakho kuqinisekisiwe kusukela kudatha yezezimali ka-Nuo no-Nord.Ngokwemiphumela yakamuva ka-2022 emenyezelwe nguNuo noNord, imali engenayo yonyaka yebhizinisi le-Nuo ne-Nord's GLP-1 ibingamabhiliyoni angama-83.371 kaDan Ying Crown (okulingana nama-yuan ayizigidi eziyizinkulungwane ezingama-81.6), okuwukukhuphuka ngo-56% ngonyaka.Phakathi kwazo, ukuthengiswa kwe-Smeglugin bekungamabhiliyoni angama-59.75 kaDan Ying Crown (okulingana nama-yuan ayizigidi eziyizinkulungwane ezingama-58.5), okuwukukhuphuka ngo-77% ngonyaka.Ukusebenza kokuthengisa kwemikhiqizo ye-GLP-1 emkhakheni wokwelapha isifo sikashukela sohlobo 2 e-China kukhuphuke ngo-102% kuDan Ying Krone.
Vele, ukuqhuma kwe-Smeglugin emkhakheni wokuncipha kwesisindo kuhlobene kakhulu nomphumela wayo obalulekile."Sekuyisikhathi sokudla, ukuphuza nokuphuza, ukuthatha amakhilogremu angu-5 wesisindo, ulahlekelwe ngamakhilogremu angu-30 ngoJanuwari" njalonjalo.Ngaphezu kwalokho, "ukulala phansi" kungaba mncane, okuye kwakhanga amehlo amaningi kuma-peptide e-Smegtu, eyaziwa ngokuthi "umuthi womlingo wokulahlekelwa isisindo".Kodwa-ke, abanye odokotela baveze ukuthi i-Simei Gulu peptide inokungaphezulu kwe-2/3 yokuthengiswa kwasekhaya e-China ukuze unciphise umzimba, hhayi isifo sikashukela.Ngakolunye uhlangothi Ngokuphathelene ne-Smeglugan peptide njengomuthi kadokotela, kunezingozi ezifihliwe ekuphepheni kwezidakamizwa ezigula kakhulu.
Kuyaphawuleka ukuthi iziphetho zocwaningo lwasekhaya zemithi enjalo zivela ezigulini ezinkulu zokukhuluphala kwabantu abadala.Kubantu abanamafutha amancane noma isisindo esijwayelekile (BM <27kg/m2), izinzuzo kanye nezingozi ezingaba khona akwaziwa.Ngaphezu kwalokho, ngaphezu kokusabela kwe-hypoglycemia okuyizidakamizwa ze-hypogenal ezenzeka emithini ye-hypoglycemic, ukusabela kwesisu kuyabonakala, futhi izehlakalo zokucanuzela kwenhliziyo, ukuqunjelwa, ukuhlanza kanye nesifo sohudo zifinyelela ku-82.8%.7%.Okubaluleke kakhulu ukuthi i-Smeglugin ayizange ivunyelwe izinkomba zokuncipha kwesisindo e-China.Inkinga yemigudu yemithi kanye nokusetshenziswa kwezidakamizwa kwabantu abanjalo kufanelekile ukunakwa.
Isikhathi sokuthumela: Aug-23-2023
.png)
